Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

NEXT STORY
Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
PREV STORY
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel

SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

author_avatar
NASDAQ Market News

The Global Ultrasound Market (2019-2023): Current Trends, Market Size, Revenue Forecast, Market Penetration, Market Attractiveness, in Cart-Based, Portable & Ultra-Portable Ultrasound Market

author_avatar
NASDAQ Market News

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer

author_avatar
NASDAQ Market News